newsfilter
← Latest News
GlobeNewswire·

Wave Life Sciences Reports Second Quarter 2026 Financial Results and Provides Business Update

Dosing underway in Phase 2a multidose portion of the INLIGHTTM trial of WVE-007 (INHBE GalNAc-siRNA) in individuals with obesity (BMI: 35-50 kg/m2) and comorbidities; trial will also inform WVE-007's potential in